GlaxoSmithKline - Seroxat sales fall 13% ...proving yet again this is the drug you CAN withdraw from - FIDDAMAN what is your excuse?

GSK’s cardiovascular and urogenital franchise generated 2011 turnover of £2.47 billion, a year-on-year rise of 8%. Within this, benign prostatic hyperplasia drug Avodart (dutasteride) sales reached £748 million, a leap of 20%, but blood thinner Arixtra (fondaparinux) declined 7% to £276 million. The central nervous system franchise was down 2% to £1.72 billion for the year, With Keppra (levetiracetam) contributing £53 million, up 20%, and Lamictal (lamotrigine) for seizures and bipolar disorder adding 536 million, a rise of 8%, while the antidepressant Seroxat/Paxil (paroxetine) generated £435 million sales, a fall of 13%. Oncology and emesis product contributed £693 million sales, up 2%, with breast cancer drug Tyverb/Tykerb (lapatinib) rising by the same percentage to £231 million.




http://www.thepharmaletter.com/file/110876/glaxosmithkline-4th-qtr-returns-to-profit-but-below-expectations.html




GlaxoSmithKline